EU e-Privacy Directive

This website uses cookies to manage authentication, navigation, and other functions. By using our website, you agree that we can place these types of cookies on your device.

View e-Privacy Directive Documents

View GDPR Documents

You have declined cookies. This decision can be reversed.

With the upcoming patent expiration of therapeutic antibodies, the development of generic drug substances is a growing field.

Recombinant production processes may impact various parameters of biopharmaceuticals:

  • Glycosylation pattern
  • Amino acid substitutions
  • Folding/misfolding
  • Disulfide bridging and pairing
  • N-terminal glutamine cyclization
  • Clipping
  • Deamidation (Asn -> Asp; Gln -> Glu; loss of epsilon-NH2 on Lys)
  • Oxidation (Met, His, Trp)

Proteome Factory offers many services for this challenging field:

Popular requests are:

Erythropoeitin (EPO), Darbepoetin (dEPO), Cetuximab (Erbitux™), Trastuzumab (Herceptin™), Infliximab (Remicade™), Natalizumab (Tysabri™) among others: Adalimumab, Aflibercept, Alemtuzumab, Basiliximab, Bevacizumab, Brentuximab, Canakinumab, Denosumab, Etanercept, Factor VIII, G-CSF, Golimumab, Ipilimumab, Mogamulizumab, Omalizumab, Pertuzumab, Ranibizumab, Rilonacept, Tocilizumab, Ustekinumab.

All trademarks mentioned herein belong to their respective owners.